Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Neenah Grade

Physician Assistant San Diego, CA Physician Assistant

NPI 1063865061 CMS profile 10689738

4125 Sorrento Valley Blvd Ste A, San Diego, CA 92121

Open in the dashboard

General payments

$4,844

217 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Neenah Grade of San Diego, CA is reported in the CMS Open Payments database as having received $4,844 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $922 38
2024 General $1,192 51
2023 General $1,001 40
2022 General $847 41
2021 General $882 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neenah Grade
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Neenah Grade were reported at $922. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Neenah Grade Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $882 $132 $37–$438 $132
2022 $847 $155 $48–$522 $149
2023 $1,001 $167 $52–$557 $160
2024 $1,192 $178 $55–$600 $164
2025 $922 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $907 48 payments
  2. Amgen Inc. $739 38 payments
  3. Novartis Pharmaceuticals Corporation $629 26 payments
  4. UCB, Inc. $382 17 payments
  5. AbbVie, Inc. $311 10 payments
  6. Grifols USA, LLC $261 11 payments
  7. CSL Behring $250 11 payments
  8. Lilly USA, LLC $234 9 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $128 5 payments
  10. AstraZeneca Pharmaceuticals LP $119 5 payments
  11. Other $882 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,844 217 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $582 25 payments
  2. Otezla $568 31 payments
  3. Enbrel Inflammation $406 22 payments
  4. COSENTYX $384 14 payments
  5. SIMPONI ARIA $358 25 payments
  6. STELARA $325 23 payments
  7. REMICADE $325 23 payments
  8. SIMPONI $325 23 payments
  9. Enbrel Inflammation $276 13 payments
  10. Hizentra $250 11 payments
  11. Other $2,963 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record